Drugs / CENISERTIB
CENISERTIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01097512 | Jun 2007 → Jul 2010 | malignant pancreatic neoplasm | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT01080664 | Dec 2006 → Mar 2010 | hematopoietic and lymphoid cell neoplasm | EMD Serono | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00391521 Comparator | Aug 2006 → Jun 2010 | cancer | EMD Serono | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CENISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1967878 ↗ |
| Known as | AS703569 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01080664 ↗ |
| Known as | Aurora kinase inhibitor as703569 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1967878 ↗ |
| Known as | R 763 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1967878 ↗ |
| Modality | Small molecule | — CHEMBL1967878 ↗ |